



# LPS O Antigen Plays a Key Role in *Klebsiella pneumoniae* Capsule Retention

Shweta Singh,<sup>a</sup> Jonathan J. Wilksch,<sup>a,b</sup>  Rhys A. Dunstan,<sup>b</sup> Anna Mularski,<sup>a\*</sup> Nancy Wang,<sup>a</sup> Dianna Hocking,<sup>a</sup> Leila Jebeli,<sup>a</sup> Hanwei Cao,<sup>a</sup>  Abigail Clements,<sup>c</sup> Adam W. J. Jenney,<sup>a</sup>  Trevor Lithgow,<sup>b</sup>  Richard A. Strugnell<sup>a</sup>

<sup>a</sup>Department of Microbiology and Immunology, University of Melbourne at the Peter Doherty Institute for Infection and Immunity, Melbourne, Victoria, Australia

<sup>b</sup>Infection and Immunity Program, Biomedicine Discovery Institute and Department of Microbiology, Monash University, Clayton, Victoria, Australia

<sup>c</sup>Department of Life Sciences, Imperial College London, London, United Kingdom

Shweta Singh and Jonathan J. Wilksch contributed equally to this article. Author order was determined by the corresponding author after negotiation.

**ABSTRACT** Despite the importance of encapsulation in bacterial pathogenesis, the biochemical mechanisms and forces that underpin retention of capsule by encapsulated bacteria are poorly understood. In Gram-negative bacteria, there may be interactions between lipopolysaccharide (LPS) core and capsule polymers, between capsule polymers with retained acyl carriers and the outer membrane, and in some bacteria, between the capsule polymers and Wzi, an outer membrane protein lectin. Our transposon studies in *Klebsiella pneumoniae* B5055 identified additional genes that, when insertionally inactivated, resulted in reduced encapsulation. Inactivation of the gene *walL*, which encodes the ligase responsible for attaching the repeated O antigen of LPS to the LPS core, resulted in a significant reduction in capsule retention, measured by atomic force microscopy. This reduction in encapsulation was associated with increased sensitivity to human serum and decreased virulence in a murine model of respiratory infection and, paradoxically, with increased biofilm formation. The capsule in the WaaL mutant was physically smaller than that of the Wzi mutant of *K. pneumoniae* B5055. These results suggest that interactions between surface carbohydrate polymers may enhance encapsulation, a key phenotype in bacterial virulence, and provide another target for the development of antimicrobials that may avoid resistance issues associated with growth inhibition.

**IMPORTANCE** Bacterial capsules, typically comprised of complex sugars, enable pathogens to avoid key host responses to infection, including phagocytosis. These capsules are synthesized within the bacteria, exported through the outer envelope, and then secured to the external surface of the organism by a force or forces that are incompletely described. This study shows that in the important hospital pathogen *Klebsiella pneumoniae*, the polysaccharide capsule is retained by interactions with other surface sugars, especially the repeated sugar molecule of the LPS molecule in Gram-negative bacteria known as “O antigen.” This O antigen is joined to the LPS molecule by ligation, and loss of the enzyme responsible for ligation, a protein called WaaL, results in reduced encapsulation. Since capsules are essential to the virulence of many pathogens, WaaL might provide a target for new antimicrobial development, critical to the control of pathogens like *K. pneumoniae* that have become highly drug resistant.

**KEYWORDS** encapsulation, LPS, *Klebsiella*, virulence, O antigen, capsule, retention

*Klebsiella pneumoniae* is a primary and opportunistic pathogen that causes community-acquired and nosocomial infections (1). The treatment of *K. pneumoniae* infections has become increasingly problematic, with a rise in extended-spectrum  $\beta$ -lactamase (ESBL) resistance (2), an increase that has been correlated with antibiotic misuse (3). The

**Editor** Olaya Rendueles Garcia, Institut Pasteur

**Copyright** © 2022 Singh et al. This is an open-access article distributed under the terms of the [Creative Commons Attribution 4.0 International license](https://creativecommons.org/licenses/by/4.0/).

Address correspondence to Richard A. Strugnell, [rastru@unimelb.edu.au](mailto:rastru@unimelb.edu.au).

\*Present address: Anna Mularski, Department of Physics, Chemistry and Pharmacy, University of Southern Denmark, Odense, Denmark.

The authors declare no conflict of interest.

**Received** 13 September 2021

**Accepted** 14 June 2022

**Published** 1 August 2022

resistance profile of *K. pneumoniae* extended further when it acquired the metallo- $\beta$ -lactamase NDM-1 (New Delhi metallo- $\beta$ -lactamase-1) (4, 5), which when combined with development of colistin resistance (6) severely limits practical treatment options. Thus, there is a pressing need to develop alternate means of controlling *Klebsiella* species infections, such as vaccine-mediated prophylaxis and antibody and bacteriophage therapies (7, 8).

The global phylogeny of *K. pneumoniae* is evolving (9–11), but pathogenic members of the *K. pneumoniae* species complex (KpSC) are characterized by the expression of a polysaccharide capsule that plays a vital role in the virulence of the bacterium (12); more than 80 capsular types have been identified (13, 14). KpSC capsular polysaccharides (CPSs) are immunogenic and nontoxic and have been used as immunogens in experimental human vaccines (15). A 24-valent vaccine was formulated by Cryz et al. as early as 1984 (16), but while there may be an increased frequency of K1 and K2 serotypes in clinical isolates (17, 18), and the K2 capsule is often found on hypervirulent strains (19), the presence of numerous capsular types within hospital settings (20, 21) has limited commercial development of a KpSC vaccine. Our attention has been focused instead on alternate means of controlling KpSC infections by blocking conserved mechanisms of capsule regulation, biosynthesis, secretion, and retention.

Considerable advances have been made toward understanding the biosynthesis and secretion of capsular polysaccharide in KpSC. The structural genes for capsular polysaccharide synthesis, designated *cps* genes, are located in an operon adjacent to the lipopolysaccharide (LPS) *rfb* locus (22, 23), situated between *galF* and *gnd* (24). Genes outside the capsule operon also play a role in capsule biogenesis (25–27), but capsule retention processes remain incompletely resolved. In some capsule types, there may be covalent linkage of the CPS through a conserved anchor to the cell surface (28). Noncovalent interactions between capsule polysaccharide and LPS core (27, 29) and capsule and the membrane-associated beta-barrel protein Wzi (30) have also been reported. While the capsule is protective, there are biological scenarios where reduced encapsulation may be advantageous: for example, nonencapsulated strains show increased binding to biotic and abiotic surfaces (20, 31), and reduction of encapsulation could facilitate biofilm formation. Similarly, since capsule can serve as a receptor for bacteriophage, regulation of capsule retention could provide for resistance to phage attack. The purpose of this study was to identify genes that are located outside the KpSC capsule synthesis locus that are involved in capsule biogenesis and retention. The study used transposon mutagenesis coupled with atomic force microscopy (AFM), biochemical assays, biofilm assays, and phage sensitivity combined with cell and animal biology to identify a role of the LPS-capsule interaction in bacterial virulence.

## RESULTS

**The capsule of *K. pneumoniae* B5055.** *Klebsiella pneumoniae* B5055 strain exhibits a mucoid phenotype, and measurements using atomic force microscopy (AFM) suggest a capsule thickness of 300 to 400 nm in solution surrounds the bacterial cells (Fig. 1A; see Table S1 in the supplemental material). The structural genes that encode the CPS secretion pore (*wza*, *wzb*, and *wzc*) (Fig. 1B) are located in a *cps* operon that also includes *wzi*. The gene *wzi* encodes a beta-barrel outer membrane protein, Wzi, that may be involved in capsule retention (30). The colonies of B5055 form a viscous “string” when contacted by a bacteriological loop (Fig. 1C), and a reduction or absence in string formation can be used to identify bacterial mutants with potentially reduced encapsulation.

A mini-Tn5 transposon described by Lorenzo et al. (32) was used for mutagenesis of the *K. pneumoniae* mouse-virulent strain B5055 (33). A total of 8,400 colonies were screened for capsular defects, and 53 kanamycin-resistant colonies (KpSC01 to KpSC53) were selected based on a nonmucoid colony appearance, altered string test, and a negative or reduced Maneval’s stain. The two workflows used are shown in Fig. S1A; both yielded similar results. The observed reduction in string length and Maneval staining in the transposon mutants could reflect one or more of three phenotypes resulting



promoter region of the CPS synthesis gene cluster (24). All the mutants that tested positive for a capsular defect in primary screening were examined for uronic acid, a component of the K2 CPS, in pelleted bacteria to estimate the quantity of CPS produced, secreted, and retained on the bacterial surface. Insertion mutant KpSC31, which carried a transposon insertion within the lipid A biosynthesis gene *msbB*, produced a longer string than B5055 (Fig. S1B), but a normal level of Maneval staining. The uronic acid associated with the pelleted KpSC31 was similar to the levels found in the parent strain, *K. pneumoniae* B5055 (see Fig. S2 below).


The percentage of uronic acid in *K. pneumoniae* B5055 is 22% by weight of capsular polysaccharide (34). Low levels of uronic acid are also present in the lipopolysaccharide (LPS) as galacturonic acid (GalA) (29). In order to establish the appropriate phase of growth for measuring uronic acid, uronic acid concentrations of wild-type (WT) *K. pneumoniae* B5055 were measured at different time points and at different stages of the growth curve (Fig. S3A). The levels of uronic acid associated with the bacterial pellet were strongly correlated with growth, and a standard culture optical density (OD) ( $OD_{600}$  of 0.6) was selected for analysis. The uronic acid content of pelleted *K. pneumoniae* B5055<sup>Rif</sup> in mid-log phase ( $OD_{600}$  of 0.6) was between 68  $\mu\text{g}/\text{mL}$  and 80  $\mu\text{g}/\text{mL}$ . The negative controls were *Escherichia coli* DH5 $\alpha$  and B5055  $\Delta wza \Delta waaF$ , which contains the *wza* deletion resulting in the loss of capsule secretion, and a *WaaF* mutation, which leads to an LPS truncation without uronic acid (27).

A reduction of uronic acid to more than 50% of the level in B5055 was observed in some insertion mutants that demonstrated reduced string lengths and/or capsule staining (e.g., KpSC44, KpSC45, KpSC49, and KpSC5); other mutants, including KpSC42, KpSC46, and KpSC50, had uronic acid levels equivalent to that of the negative control, B5  $\Delta wzb-c \Delta waaF$  (Fig. S2). The small amounts of uronic acid present in B5055  $\Delta wza$  were attributed to the GalA present in the LPS (29), since B5055  $\Delta wza \Delta waaF$  had reduced levels of uronate compared with the capsule-deficient B5055  $\Delta wzb-c$  strain, which expresses normal LPS (31).

We concluded that the approach of using the string test and Maneval's capsule stain identified mutants that have defects in encapsulation, and further studies were undertaken to resolve the biology of these defects.

**LPS O-antigen mutants are capsule deficient.** Seven transposon insertions were found within the operons required for complete LPS synthesis (Fig. 2A; Table S3), and these insertions were in the genes *wabK*, *wabM*, and *waaL*. Two independent *waaL* transposon insertion mutants, KpSC47 and KpSC48 (Table S3), were analyzed for serum sensitivity (Fig. 2B). Like the capsule-deficient mutant B5055  $\Delta wzb-c$ , these strains exhibited sensitivity to killing by normal human serum (i.e., containing complement), but were as resistant as B5055 to complement-inactivated normal human serum. The putatively enhanced complement sensitivity may have come from the loss of capsule: the B5055  $\Delta wzb-c$  mutant carries intact LPS (Fig. 3B), and this defined mutant was sensitive to killing by human complement. Uronic acid analysis of B5055  $\Delta waaL$  and a complemented construct (B5055  $\Delta waaL-C'$ ) suggested that complementation increased uronic acid levels in the pelleted bacteria (Fig. 2C).


LPS consists of O-antigen polysaccharides ligated to the LPS core, which is embedded in the KpSC membrane via lipid A (Fig. 1B). B5055 has an O antigen that is serotype O1 with a type 2 *lps* core (35), with the O glycan a repeated polymer of alpha- and beta-linked galactose (Fig. S3B). The core contains 2 GalA sugars (Fig. S3C). Transposon insertions that lead to a capsule-deficient phenotype were found in 3 *lps* core synthesis genes: *wabM*, *wabK*, and/or *waaL*. These gene products act "distally" to the  $\alpha$ -GalA sugars that have been linked with capsule retention (27, 29) (Fig. 2D, highlighted in green). In the absence of *wabM* or *wabK*, the substrate for *WaaL* [i.e.,  $\beta$ -Glc (1 $\rightarrow$ 6)] (Fig. 2D) would not have been added. Transposon insertions in LPS biosynthesis genes that generated a reduced string suggest that there is a relationship between LPS biosynthesis and encapsulation. Mutants KpSC01, KpSC15, KpSC33, KpSC04, KpSC47, KpSC48, and KpSC52 had uronic acid levels that were <50% of that of B5055.



**FIG 2** Transposon insertions into LPS-associated genes may have reduced capsules. (A) Eight capsule mutants were found to have transposon insertions within lipopolysaccharide biosynthesis genes of B5055; seven were within the *waa* operon. The insertions identified in the capsule-deficient screen are denoted by green arrowheads. (B) The sensitivity of various *K. pneumoniae* B5055 strains to human serum killing was evaluated in an assay where bacteria were exposed to normal human serum (NS) or heat-treated human serum (HTS) for 90 min. The viable counts were expressed as the fold change ratio from the starting inoculum for each isolate after 90 min. The values represent the mean and standard error of the mean (SEM) from 3 biological replicates and were analyzed using a two-way analysis of variance (ANOVA) with Bonferroni's posttest adjustment for multiple testing. \*,  $P < 0.05$ ; \*\*,  $P < 0.01$ ; ns, not significant. (C) Uronic acid was measured in the pellets of *K. pneumoniae* B5055 (WT) and in selected mutants. Uronic acid was estimated in bacterial pellets of mid-log samples, and the histograms are the mean and SEM from 3 biological replicates. (D) O1 LPS structure of B5055 inferred from reference 29. The glycosyltransferases that add onto each of the sugars are denoted. The LPS insertions that affected encapsulation are shown in red. The urinate-containing sugars are shown in green. For orientation, the LPS is embedded in the membrane through lipid A (RHS), and the O antigen is added to the LHS.

Capsule-deficient transposon insertions outside the *cps* and *lps* operons were observed within 12 independent capsule mutants of B5055 (Table S4). Two transposon insertions were found within the virulence plasmid pLVPK: one within the *iroC* gene and another in *pyrC* gene. In both mutants (KpSC12 and KpSC49 [*iroC* and *pyrC*, respectively]), there was no string formation, and the uronic acid concentrations were <50% of that of the wild type (Fig. S2). Mutants with insertions in *uge* (KpSC19) and *galU* (KpSC03, KpSC09, and KpSC42) had very low levels of uronic acid, equal to that of B5055  $\Delta wza \Delta waaF$ , suggesting a deficiency of both LPS and capsule.

A defined *WaaL* ( $\Delta waaL$ ) deletion mutant was constructed in B5055; this mutant had a string length approximately 15 to 25% of that of B5055 (Fig. 3A). To ensure that



**FIG 3** Loss of O antigen is associated with capsule loss. (A) The string test length was used to examine the relative contributions of WaaL and LPS O antigen to capsule retention. The strains tested were B5055 (WT), the capsule mutant (B5055  $\Delta wzb-c$ ; capsule-deficient “smooth LPS”), the defined WaaL mutant (B5055  $\Delta waaL$ ), and the complemented defined WaaL mutant (B5055  $\Delta waaL-C'$ ) with pACYC184 expressing WaaL from the Tet<sup>r</sup> promoter. The values represent the mean and SEM from 3 biological replicates. (B) Silver stain and Western blotting were used to study the LPS phenotype in each strain. LPS preparations from *K. pneumoniae* strains were separated by Tricine-SDS-PAGE on 15% gels and visualized by a modified silver staining method or transferred to nitrocellulose for incubation with monoclonal antibody I12, specific for the O1 LPS of *K. pneumoniae* (60). The Western blot of the WaaL mutant (B5055  $\Delta waaL$ ) showed the presence of polymerized O antigen in the WaaL mutant, albeit of reduced intensity. This strain was negative by silver stain. Complementation of the WaaL mutant with pACYC184 expressing WaaL from the Tet<sup>r</sup> promoter (B5055 $\Delta waaL-C'$ ) restored LPS, producing silver-stained and

(Continued on next page)

the capsule phenotype in B5055  $\Delta waaL$  was not due to second-site compensatory mutations, the *waaL* gene was expressed from the Tet<sup>r</sup> promoter present in pACYC184, and this plasmid was used to complement the defined mutant. The complementary construct was transformed into B5055  $\Delta waaL$  (forming B5055  $\Delta waaL-C'$ ), and complementation doubled the string length (Fig. 3A) to approximately 50% of that of the parent B5055 strain.

The defined WaaL mutant and the complemented WaaL mutant were analyzed by silver staining, Western blotting, and by flow cytometry for LPS synthesis and surface expression/retention of the capsule. Silver-stained gels revealed the loss of the LPS "ladder" from B5055  $\Delta waaL$  (Fig. 3B, lane 3) and restoration of an LPS ladder in B5055  $\Delta waaL-C'$  (Fig. 3B, lane 4). The O1-antigen-specific monoclonal antibody I12 (31) was used in Western blots of these preparations and revealed that the B5055  $\Delta waaL$  strain synthesized the high-molecular-weight O antigen (Fig. 3B, lane 3), but it was of a slightly lower molecular weight and produced at lower levels that were not seen in the silver stain gel, but which were visualized by Western blotting (Fig. 3B). The LPS core (shown by an arrow for the silver stain) appeared to be present in at least equal amounts in B5055 and the B5055  $\Delta waaL$  mutant. This observation suggests that the WaaL mutant synthesized the O antigen, but did not ligate the O antigen to the lipid carrier for transport to the outer membrane.

To test this hypothesis, live bacteria were stained with antibody I12 and analyzed for surface fluorescence by flow cytometry (Fig. 3C). B5055 (WT; red) was brightly fluorescent, with a mean fluorescent intensity (MFI) that was 50-fold higher than that of the negative control (B5055  $\Delta wza \Delta waaF$ , a capsule mutant lacking the O antigen [green]). The B5055  $\Delta waaL$  mutant (blue) demonstrated I12 surface fluorescence equivalent to that of B5055  $\Delta wza \Delta waaF$ . The complemented mutant (B5055  $\Delta waaL-C'$  [brown]) exhibited I12 staining equivalent to that of B5055, whereas an additional control in which B5055  $\Delta waaL$  was complemented with the empty vector (B5055  $\Delta waaL-CV$  [purple]) was also negative for surface expression of the I12 epitope. The WaaL and complemented WaaL mutants of B5055 were then analyzed by AFM for capsule thickness.

To quantify how much capsular polysaccharide was retained on the surface of the B5055  $\Delta wzb-c$  and B5055  $\Delta waaL$  mutants, the capsule thickness was measured by atomic force microscopy (Fig. 3D) (Table S1). The measured capsule thickness from AFM force curves generated for the various strains revealed a capsule thickness of 377 nm on the B5055 strain, consistent with previous studies using AFM (36). The mutant B5055  $\Delta wzb-c$ , which lacks capsule due to the absence of the *wzb-wzc* capsule translocon, had a surface layer that radiated approximately 26 nm, the presumed length of the LPS O antigen in solution. The B5055  $\Delta waaL$  mutant had a mean capsule thickness of 188 nm, approximately half that of B5055, which was restored to near-wild-type levels (mean, 316 nm) by complementation (B5055  $\Delta waaL-C'$ ). During the preparation of the bacterial samples, it was noted that the cell pellets from the wild-type B5055 and the B5055  $\Delta waaL-C'$  strain were similar in size and friability and distinct from the compacted pellets of the B5055  $\Delta wzb-c$  and  $\Delta waaL$  mutants (Fig. S4).

Finally, virulence tests of the parental strain B5055, the nonencapsulated B5055  $\Delta wzb-c$  mutant, the B5055  $\Delta waaL$  mutant, and the complemented ( $\Delta waaL-C'$ ) mutant were conducted. Groups of 9 to 15 C57BL/6 mice were intranasally inoculated with

### FIG 3 Legend (Continued)

Western blot patterns that were similar to those in the wild-type B5055 and mutant (B5055  $\Delta wzb-c$ ) LPS profiles. (C) Flow cytometry of difference mutants of *K. pneumoniae* B5055 stained with antibody I12 to determine O-antigen surface expression. The 5 strains tested were B5055 (WT), B5055 with *wzb-c* and *waaF* deleted (B5055 $\Delta wzb-c\Delta waaF$ ), the defined WaaL deletion mutant (B5055  $\Delta waaL$ ), and the mutant B5055  $\Delta waaL-CV$  complemented with the empty complementation vector (pACYC184) or with pACYC184 expressing WaaL from the Tet<sup>r</sup> promoter (B5055  $\Delta waaL-C'$ ). (D) Capsule thickness of the WaaL mutant (B5055  $\Delta waaL$ ) and the complemented WaaL mutant (B5055  $\Delta waaL-C'$ ) was measured by AFM. Cells were imaged in contact mode at a scan rate of 1 Hz at room temperature. The cell apex was probed during force measurements (82). The histograms represent the mean and SEM from 30 to 40 bacteria for each mutant for capsule thickness. (E and F) Groups of 10 to 12 C57BL/6 mice were inoculated intranasally with  $5 \times 10^4$  cells of *K. pneumoniae* B5055 or the various mutants and monitored for weight loss for 3 days (E). (F) After 3 days, the animals were killed and the viable count of *K. pneumoniae* estimated by plating of serially diluted lung homogenates onto LB agar. Groups were compared using a one-way ANOVA.


$5 \times 10^4$  CFU, observed for 3 days, and measured for weight loss (Fig. 3E), where increased weight loss is associated with more severe disease. On day 3, the mice were killed, and lungs were removed to count viable bacteria in the tissues (Fig. 3F). The mean bacterial count in the lungs was highest in mice inoculated with B5505. The non-encapsulated mutant (B5055  $\Delta wzb-c$ ) was not recovered from the lungs of inoculated mice. Compared with B5055, the recovery of the B5055  $\Delta waaL$  mutant was significantly reduced ( $P < 0.0001$ ). In the complemented mutant, growth of the bacteria in the lungs was significantly increased ( $P < 0.016$ ) compared with the B5055  $\Delta waaL$  mutant (Fig. 3E).

**Comparison of the WaaL and Wzi mutants for capsule retention.** The B5055  $\Delta wzb-c$  mutant lacking the functional secretion pore has no exopolysaccharide capsule, as judged by string length measurements (Fig. 3A) and reduced uronic acid analysis (Fig. 2C); the small amounts of urinate in the  $\Delta wzb-c$  mutant are likely contributed by the galacturonic acid present in the LPS core (Fig. 2D). The B5055  $\Delta waaL$  mutant retained less than 50% of the capsule polysaccharide on its surface (Fig. 3D), suggesting that the distal chains of the O antigen provide an anchor or stabilizer for the capsule. To address previous observations that Wzi contributes to capsule retention (30, 37), we constructed two further mutants, B5055  $\Delta wzi$  and B5055  $\Delta waaL \Delta wzi$ , to determine whether Wzi was acting in concert with WaaL to retain capsule.

Again, the capsule translocon mutant ( $\Delta wzb-c$ ) generated no string, while the WaaL and Wzi single mutants and WaaL Wzi double mutant all showed reduced string lengths compared with B5055 (Fig. 4A). The level of uronic acid associated with the cell pellet in the Wzi mutant was greater than that for the WaaL mutant, and the WaaL Wzi double mutant had further reduced levels of urinate compared to the WaaL mutant (Fig. 4B). In the human whole-blood assay (Fig. 4C), growth of B5055 was observed over the incubation period in blood. In comparison, there were declines in the bacterial counts of the capsule translocon mutant ( $\Delta wzb-c$ ) and the O-antigen ligase mutant ( $\Delta waaL$ ) in whole human blood, while there was growth in the complemented WaaL mutant ( $\Delta waaL-C'$ ). The loss of Wzi ( $\Delta wzi$ ) had limited impact on the survival of the bacteria, but net growth was not observed, and the double mutant without WaaL and Wzi had a loss-of-viability phenotype similar to that of the WaaL mutant.

**Biofilm formation and bacteriophage sensitivity.** The impact of mutation of WaaL and loss of O antigen from LPS on biofilm formation was then investigated (Fig. 4D). *K. pneumoniae* B5055 is a poor biofilm former because it lacks an intact copy of the Mrk activator MrkH (38). B5055 and the various mutants were complemented with a pACYC184 plasmid carrying MrkHI, expressed from the endogenous promoter (*pmrkHI*) (38). The isolates were then analyzed for static biofilm formation at 24 h post-inoculation, using crystal violet staining (38) (Fig. 4D). The data were divided into two groups: those without *pmrkHI* (group A) and those with the plasmid expressing the positive regulator of the Mrk fimbriae (group B). Biofilm formation in B5055 was strongly increased by transformation with the plasmid expressing MrkHI. The highest level of biofilm formation was in the positive control, which lacks the capsule translocon. The WaaL mutant also showed statistically significant increases in biofilm formation compared with the wild type (WT), whereas the increase in biofilm formation seen with the Wzi mutant compared with the wild type was smaller and not statistically significant.

Finally, the sensitivity of the WaaL and Wzi mutants to bacteriophage RAD2 was examined. RAD2 requires the K2 capsule as a receptor for infection (Fig. 4E). Previous studies have shown that the B5055  $\Delta wza \Delta waaF$  mutant lacking the O antigen and the *wzb-c* mutant lacking the secretion pore are completely phage resistant (39). As expected, clear RAD2 plaques formed on B5055, but not on the Wza capsule-deficient mutant. The WaaL mutant show a reduced number of turbid plaques, suggesting inefficient binding, whereas infection of the complemented WaaL mutant produced normal plaques. Normal plaques were formed by RAD2 on the Wzi mutant, but the Wzi WaaL double mutant had a phenotype similar to that of the WaaL mutant. These data



**FIG 4** Contribution of WaaL and Wzi to capsule retention in *K. pneumoniae*. To examine the relative contributions of Wzi and LPS O antigen to capsule retention, the wild-type B5055 strain, single mutant strains ( $\Delta wzb-c$ ,  $\Delta wzi$ ,  $\Delta waaL$ , and complemented  $\Delta waaL$ ) (C and E), and double mutant strain ( $\Delta waaL\Delta wzi$ ) (Continued on next page)

suggest that WaaL is required for full sensitivity to RAD2, a phage specific for the K2 capsule.

## DISCUSSION

The production and retention of an exopolysaccharide capsule are critical steps in the virulence of many bacterial pathogens, and while there is a good understanding of how the capsular polymers are synthesized and secreted (40), much less is understood about the retention of the capsule on the bacterial cell surface. In Gram-negative bacteria, some of the capsule polymers may be linked to the bacterial outer envelope through a lipid carrier. In so-called “group 2” capsules (41), a poly-2-keto-3-deoxyoctulosonic acid (poly-KDO) linker is attached to a lysophosphatidylglycerol lipid moiety that can embed within the cell envelope (28, 42). However, this may not be true for all the individual capsular carbohydrate polymer chains or for group 1 capsules. Better resolution of the mechanism of capsule retention might assist the development of strategies to deencapsulate pathogens, rendering them much more sensitive to innate defense mechanisms, and hence less virulent.

Our studies sought to identify genes involved in encapsulation that sat within and outside the major capsule locus, using transposon mutagenesis of a heavily encapsulated, virulent strain of the opportunistic pathogen *K. pneumoniae*, known as B5055. B5055 is mouse virulent (43), expresses O1 LPS and K2 capsule, and was first described by Goslings and Snijders (44). Mutations that might affect encapsulation could act at various levels—there are biochemical processes involved in capsule polymer synthesis, capsule polymer secretion, and capsule retention that might all affect the capsule phenotype of a bacterial pathogen. In a transposon screen using simple, high-throughput phenotypic approaches (e.g., measuring string length supported by Maneval staining for capsule), it was not possible to differentiate the cause of deencapsulation without further analysis. This was enabled by uronic acid assays, staining reactions, flow cytometry, and AFM. The biological effects of these mutations were analyzed in bacterial survival assays *in vitro* and *in vivo*.

A total of 8,400 colonies were screened for capsular defects following random transposon mutagenesis of B5055, from which 53 mutants were further analyzed for string length and uronic acid production. One mutant produced much longer strings. While the string test is not fully understood, nonencapsulated mutants of B5055 form very short strings compared with the parent, B5055. Thirty-nine mutants that had reduced string test values and reduced urate production were analyzed by Y-linker PCR for the insertion site of the transposon. The query sequences showed more than 98% nucleotide identity to the homologous genes present in the “reference” *K. pneumoniae* MGH 78578 genome or the *cps* gene cluster of the *K. pneumoniae* Chedid strain (also an O1:K2 strain), or the *waa* operon of *K. pneumoniae* 52145 (O1:K2). Some genes associated with reduced string lengths were independently mutagenized multiple times by albeit nonsibling transposon insertions. After the screen and Y-linker analysis, insertions were identified in 22 different open reading frames that yielded a capsule-defective phenotype in *K. pneumoniae* B5055, including 6 genes (with a total of 19 independent insertions) known to be directly involved in capsule synthesis, such as *wza* and *wzc*, which form part of the translocon (see Table S2 in the supplemental material), providing a validation of the approach. Four insertions were found in *lps* biosynthesis gene cluster,

### FIG 4 Legend (Continued)

$\Delta wzi$ ) were analyzed for (A) string test length, (B) uronic acid levels associated with the bacterial pellets, and (C) survival in unheated human serum for 90 min, as previously described. The mutants were also tested for (D) formation of static biofilms. In panels A to C, the histograms represent the mean and SEM from 3 biological replicates, and the different strains were compared using a one-way ANOVA. For biofilm measurements (D), B5055 and the deletion mutants were tested with (group B) and without (group A) transformation with a plasmid expressing MrkH (59). MrkH is a cyclic-di-GMP-sensitive transcriptional activator of Mrk fimbria expression that has been naturally deleted from B5055, resulting in poor biofilm formation. The bacteria were added to the wells under optimized conditions and left for 24 h, and the wells were stained with crystal violet. The binding of crystal violet was determined using acetic acid solubilization, and absorbance was measured at 595 nm in a spectrophotometer. The mean and SEM from each sample (3 biological replicates, 5 technical replicates of each) were compared with those of the parent WT strain by one-way ANOVA (E). The strains were also tested for their sensitivity to a K2-specific bacteriophage, RAD2, in a plaque assay (39). The number and type of plaques reflect the sensitivity of each of the mutants to RAD2.

10 genes were found outside both *cps* and *lps* operons, but in the bacterial chromosome, and 2 genes were found in the plasmid pLVPK.

One mutant, KpSC31, displayed an increased string length. This mutant carried a transposon insertion in *lpxM/msbB*, which codes for lipid A lauroyl acyltransferase according to the Raetz pathway (45). During the final steps of lipid A biosynthesis in *E. coli*, acyloxyacyl moieties are generated by addition of lauroyl and myristoyl residues to the distal glucosamine unit (45). Mutation in the *lpxM* gene in *E. coli* leads to attenuation in the mutants for activation of human macrophages (46), although the gene is not essential for growth (47), *lpxM* expression is a virulence trait in the murine model of *E. coli* pathogenicity (48). In *Salmonella*, mutations in the *lpxM* gene render the mutants less lethal than the wild-type strain in animal septic shock models (49, 50). In *K. pneumoniae* B5055, mutation in *lpxM* renders the bacterium attenuated for growth and less lethal in mouse pneumonia models (51). The reasons why the *lpxM* insertion mutant gave rise to a grossly increased string length were not explored, but there was no increase in uronic acid associated with the mutant, suggesting that increased string length may not always be reflective of increased encapsulation, but might result from, e.g., the strength of interactions between carbohydrate polymers and the outer envelope through lipid A, which is hexa-acylated by LpxM, or the length of the capsule polymer chains.

This study suggests that generation of wild-type levels of bacterial encapsulation in the archetypical encapsulated Gram-negative bacterium *K. pneumoniae* is a complex phenomenon involving genes directly required for capsule biosynthesis and numerous other genes outside the capsule locus, such as *degP*, coding for a periplasmic protease (52), *teqK*, coding for a putative efflux/permease protein with homology to the 14-transmembrane-domain DHA2 family of the major facilitator superfamily (MFS) (53), and *ompW*, an 8-stranded beta-barrel protein that provides *E. coli* with enhanced resistance to phagocytosis and complement resistance (54).

The capsule-deficient mutants that contained transposon insertions in the *lps* operons were in enzymes that synthesized the relatively conserved LPS carbohydrate core and typically core synthesis distal to the GalA (galacturonic acid) residue(s)—in *wabK* and in *wabM* (Fig. 2D). Previous studies suggested that the capsule-retentive interaction between LPS and capsular polysaccharides was mediated through ionic interactions between capsule “fibrils” and the LPS core galacturonic acids (GalA), a distal sugar on the branch of the LPS core carbohydrate that is also present in the “unbranched” LPS core (29). Our data suggested that the interaction between the attached polymerized O antigen and the capsule monomers stabilizes capsule retention.

Three independent capsule-deficient mutants were identified with insertions within *waal*, the O-antigen ligase that attaches O antigen to the completed LPS core (55); according to the published structures of the *K. pneumoniae* O1 LPS, each of these mutants retained at least 1 GalA in the rough LPS that was synthesized. *WaaL* mutants are attenuated for *in vitro* inflammation (56) and *in vivo* in a murine septicemia model (29). To explore the relationship between O antigen and encapsulation further and to remove the potential confounding effects of transcriptional polarity from the transposon, a defined “gene-gorged” mutant with *waal* mutation was constructed and complemented. This defined *waal* mutant phenocopied the transposon insertion into *waal* and was capsule deficient. Interestingly, the defined *waal* mutant continued to synthesize the LPS O-antigen polymer, as determined by Western immunoblotting. Flow cytometry showed that this O antigen was not on the bacterial surface, however, and that the significant loss of encapsulation in the *waal* mutant, defined by AFM, was restored when the *waal* mutant was complemented (Fig. 3D; Table S1). The *waal* mutant was attenuated for growth in mice compared with the B5055 parent strain, but retained virulence for mice in a pneumonia model beyond that of the B5055  $\Delta wza$  nonencapsulated strain. The relative roles of Wzi, the surface lectin involved in capsule assembly (30, 57), were also assessed by mutagenesis. The loss-of-capsule phenotype was greater in the *WaaL* mutant than in the *Wzi* mutant, and the *WaaL* mutant, like the

capsule-deficient mutant ( $\Delta wzb$ -c), did not support efficient growth of the K2-specific RAD2 bacteriophage.

The apparent paradox, whereby increased biofilm formation was reported in non-encapsulated mutants of *K. pneumoniae* (58), is consistent with our observations that the WaaL mutant formed larger biofilms. In *K. pneumoniae*, biofilm formation on plastic substrates is dependent on Mrk fimbriae (59), and B5055, the strain used in this study, does not naturally form biofilms because it lacks the transcriptional activator of the Mrk fimbriae, MrkH (59). This gene was provided as a plasmid to test whether the WaaL mutation affected biofilm formation. Previous studies had suggested that Mrk-mediated biofilm formation was enhanced when capsule was deleted (20, 60). The mutation of WaaL had a greater positive impact on biofilm formation than the loss of Wzi, and addition of a Wzi mutation to the WaaL mutation further increased biofilm formation, suggesting that the WaaL and Wzi functions may not be redundant with respect to biofilm production. The reason for the increase in biofilm when encapsulation is reduced is likely explained by greater Mrk fimbrial access to the polycarbonate substrate on which the biofilms formed, though the mechanoproperties of the capsule are also altered by fimbriae (61, 62). These data suggest that the degree of encapsulation, and hence, inversely, biofilm formation, may be regulated by one or more of the multiple mechanisms known to increase the chain length of the O antigen (63).

These data very strongly suggest that capsule retention in *Klebsiellae* is stabilized by an interaction between surface oligosaccharides present in the O-antigen component of the LPS and the individual capsule fibrils (Fig. 5). An alternate, albeit less likely, hypothesis that WaaL directly ligates the capsule polymer to the core of LPS, matured by WabK and WabM, was not investigated. To rule out effects of accumulated O antigen on *cps* transcription, we quantified the transcription of key *cps* genes in the wild type and WaaL mutant strains of B5055. There were no obvious differences in *cps* transcription in the wild-type B5055 and WaaL mutant B5055 (Fig. S5).


The interaction between the LPS O carbohydrate and the capsule monomer could occur physically, through entwining of capsule polymer fibrils with fully polymerized and ligated O antigen, or the LPS may help stabilize long polymers, anchored into the outer membrane through a covalently associated glycolipid moiety, or noncovalently via the core GalA sugars. Finally, while O-antigen–capsule monomer interactions would not explain capsule retention in some Gram-negative pathogens, like *Neisseria meningitidis* and *Haemophilus influenzae*, which express an oligosaccharide LPS only (64, 65), our findings suggest that LPS-based vaccines that induce antibodies that drive complement-mediated lysis or phagocytosis of *K. pneumoniae* through binding to O antigen may have an additional protective benefit through reducing encapsulation. Moreover, the data suggest that *Klebsiella* biofilm formation, which is seen as a key virulence trait that is mediated through Mrk fimbriae and important in colonization of plastics (59), may be regulated through processes that control the length of the O antigen.

## MATERIALS AND METHODS

**Strains.** *Klebsiella pneumoniae* B5055 is a mouse-virulent, O1:K2 strain of *K. pneumoniae* and was the generous gift of D. Hansen from the Statens Serum Institute, Copenhagen. The derivatives used in this study are shown in Table 1. The *Escherichia coli* S17-1  $\lambda$ pir strain containing the pUT vector harboring the transposon miniTn5Km2 was used in the transposon mutagenesis (32). The capsular mutant B5055  $\Delta wzb$ -c was the result of site-directed mutagenesis of the *wzb* and *wzc* genes of CPS synthesis using the Lambda Red recombinase system, as described in reference 31.

**Transposon mutagenesis.** The mini-Tn5 transposon was delivered from a mobilizable pUT plasmid, containing the  $\pi$  protein-dependent origin of plasmid R6K and harboring the Tn5 transposase, which sits outside the transposable resistance cassette. Since *K. pneumoniae* B5 carries no innate antibiotic resistance that could be utilized for selection, a rifampin-resistant derivative of B5055 was used. B5055<sup>Rif</sup> was created by plating the parent strain (wild-type B5055) on a gradient of rifampin and selected from spontaneously resistant mutants (66). Transposon mutants were created by conjugation of *E. coli* S17-1  $\lambda$ pir strains containing pUT vector harboring the transposon miniTn5Km2 with *Klebsiella pneumoniae* strain B5055<sup>Rif</sup>, serotype K2.

**String test.** Each mutant was cultured for single colonies for 18 h on LB agar. The formation of a string was determined using a bacteriological loop. The maximal length of the string formed was measured in centimeters, recorded from at least three independent colonies.



**FIG 5** Amended model for capsule retention by *K. pneumoniae*. The association between the O antigen in the LPS and the polysaccharide capsule occurs through unresolved forces and possibly simple entanglement of the fibrils. The O antigen is shown in red and the core oligosaccharide in blue. Some capsule types may use an acylated carrier (pink) to link the capsule fibril to the bacterial surface. The ligation of LPS O antigen is required for maximal capsule retention, and Wzi plays a minor role in capsule retention, possibly through its properties as a lectin (57).

**Maneval's stain.** A drop of 1% (wt/vol) Congo red dye was placed on a glass slide, and a loop of bacteria was mixed gently into the drop of dye. The stain was air dried and counterstained with Maneval's stain (acetic acid and acid fuchsin) for 2 to 3 min. The slide was washed in distilled water, air dried, and examined under oil immersion. The degree of encapsulation was compared with those of B5055 and B5055  $\Delta wzb-c$  (67).

**Uronic acid quantification.** The measurement of uronic acid for quantification of CPS in *K. pneumoniae* was performed as described previously (68). The modified carbazole assay uronic acid measures uronic acids, including glucuronic acid, one of the four sugars present in the CPS of *K. pneumoniae* K2 (69, 70). Uronic acid is present in the LPS of *K. pneumoniae* B5055; as an O1:K2 isolate, the percentage of glucuronic acid in *K. pneumoniae* K2 strain B5055 should be 21.6% by weight of CPS (29, 34). The relationship between glucuronic acid and absorbance at 520 nm was linear up to a concentration of 200  $\mu\text{g}/\text{mL}$ . The measurements were performed in microtiter plates (71). Single colonies were inoculated into LB broth and incubated overnight at 37°C with shaking. Overnight cultures were diluted in 1/50 LB broth and grown at 37°C with shaking to obtain mid-log cultures ( $\text{OD}_{600} = 0.6$ ). Three biological replicates were taken for each mutant, culture density was measured at 600 nm, and CPS extraction was carried out by the method of Campos et al. (68). The amount of uronic acid was determined by measuring absorbance at 520 nm following addition of 0.15% 3-hydroxy-diphenol in 0.5% NaOH (68–70), and the readings were compared with a standard curve of uronic acid.

**Transposon mutagenesis.** The mini-Tn5 transposon was delivered from a mobilizable pUT plasmid containing the  $\pi$  protein-dependent origin of plasmid R6K. Since *K. pneumoniae* B5 carries no innate antibiotic resistance that could be utilized for selection, a rifampin-resistant derivative of B5055 was used. B5055<sup>Rif</sup> was created by plating the parent strain (wild-type B5055) on a gradient of rifampin and selected from spontaneously resistant mutants (66). Transposon mutants were generated by conjugation of *E. coli* S17-1  $\lambda\text{pir}$  strains containing the pUT vector harboring the transposon miniTn5Km2 with *Klebsiella pneumoniae* strain B5055<sup>Rif</sup>, serotype K2. Mid-log cultures of donor (*E. coli* S17-1  $\lambda\text{pir}$  harboring

**TABLE 1** Bacterial strains and plasmids used in this study

Strain or plasmid	Characteristic(s) <sup>a</sup>	Reference or source
<b>Strains</b>		
<i>K. pneumoniae</i> B5055	Wild type, encapsulated <i>K. pneumoniae</i> O1:K2	33; data not shown
<i>K. pneumoniae</i> B5055 <sup>Rif</sup>	Rifampin-resistant derivative of B5055	This study
<i>K. pneumoniae</i> B5505Δwzb-c	Defined <i>wzb-wzc</i> functional capsule translocon deletion of B5055, capsule deficient, wild-type O1 LPS	20
<i>E. coli</i> DH5α	Nonencapsulated, deep rough mutant of <i>E. coli</i> K-12, recombination-impaired cloning strain	Thermo Fisher Scientific
<i>E. coli</i> S17-1 λpir	Donor strain for conjugational transfer of transposons, carries suicide plasmid pUT harboring mini-Tn5Km2 transposon, Km <sup>r</sup>	58
<i>K. pneumoniae</i> B5505 Δwza ΔwaaF	B5505 Δwza carrying a mutation in WaaF, no capsule or LPS O antigen	31
<i>K. pneumoniae</i> KpSC01-KpSC53	Tn5 transposon insertions into B5055 <sup>Rif</sup>	This study
<i>K. pneumoniae</i> KpSC47, KpSC48	Independent Tn5 insertions into <i>waaL</i> gene of B5055	This study
<i>K. pneumoniae</i> B5055 ΔwaaL	B5055 with <i>waaL</i> deleted	This study
<i>K. pneumoniae</i> B5055 ΔwaaL-C'	B5055 ΔwaaL carrying pACYC184::waaL	This study
<i>K. pneumoniae</i> B5055 ΔwaaL-CV	B5055 ΔwaaL carrying pACYC184	This study
<i>K. pneumoniae</i> B5055 Δwzi	B5055 with <i>wzi</i> deleted	This study
<i>K. pneumoniae</i> B5055 ΔwaaL Δwzi	B5055 with <i>waaL</i> and <i>wzi</i> deleted	This study
<i>K. pneumoniae</i> KpSC01-KpSC53	Independent Tn5 insertions of B5055 <sup>Rif</sup> having a string test difference	This study
<b>Plasmids</b>		
pACYC184	Medium-copy-no. vector, Cm <sup>r</sup> Tc <sup>r</sup>	75
pACYC184::waaL	pACYC184 containing B5055 <i>waaL</i> gene inserted under control of TetR promoter, Cm <sup>r</sup>	This study
pGEM-T Easy	High-copy-no. vector, Ap <sup>r</sup>	Promega
pACBSR	Mutagenesis plasmid, carries genes for I-SceI endonuclease and Lambda Red recombinase	73
pKD4	Vector containing Km <sup>r</sup> gene, Ap <sup>r</sup> Km <sup>r</sup>	74

<sup>a</sup>Ap<sup>r</sup>, ampicillin resistance; Cm<sup>r</sup>, chloramphenicol resistance; Km<sup>r</sup>, kanamycin resistance; Tc<sup>r</sup>, tetracycline resistance.

suicide vector pUT-mini-Tn5Km2) and recipient (*K. pneumoniae* B5055<sup>Rif</sup>) were mixed in a 1:1 ratio in a final volume of 1 mL. The conjugation mixture was then centrifuged, resuspended in 0.1 mL LB, and grown on LB agar for 6 h. Bacterial lawn growth was resuspended in LB, diluted 1:100, and replated onto LB agar containing kanamycin and rifampin. A total of 8,400 kanamycin- and rifampin-resistant colonies were streak diluted on LB agar containing kanamycin and subsequently stored in LB containing 10% glycerol and kanamycin at -70°C until required. The sequences flanking the transposon insertions were amplified by Y-linker ligation PCR (72).

**Y-linker mapping of transposon insertions.** The Y-linker method uses a Y-shaped linker that was designed to have a 3' overhang complementary to the "sticky end" generated by the restriction enzyme digestion of the chromosome (72). Electrophoretic analysis of the PCR amplicons following Y-linker ligation PCR determined that for the mutants selected, the transposon had inserted only once into the genome. The PCR product was sequenced to identify the insertion site.

**Construction of clean deletions.** Gene gorging (73) was used to construct clean deletion mutants in *K. pneumoniae* B5055 using a two-plasmid system. The mutagenesis plasmid pACBSR carries the genes for I-SceI endonuclease and the λ Red recombinase, under the inducible control of the arabinose promoter (74). Approximately 0.5-kb regions flanking the upstream and downstream sequence of the target gene were PCR amplified using the I-SceI primers on the *K. pneumoniae* B5055 strain as the template. The kanamycin resistance gene was amplified from pKD4, using KanF and KanR primers, such that the resulting product contains fragment length polymorphism recombinase target (FRT) sites to permit subsequent excision of kanamycin cassette. The excision of the kanamycin cassette from the chromosome of the deletion mutants used the helper plasmid pCP20. The temperature-sensitive plasmid pCP20 was removed by incubation at 42°C and the genotypes confirmed by PCR.

**Complementation of WaaL.** The gene encoding WaaL was amplified from *K. pneumoniae* B5055, ligated into pGEM-T Easy, and sequenced. The constructs were gel isolated after restriction enzyme digestion and inserted within either the tetracycline or chloramphenicol resistance-encoding genes of pACYC184 (75) via unique restriction sites. In pACYC184::waaL, the plasmid contained B5055 DNA that was transcribed from the Tet<sup>r</sup> promoter (i.e., in the same direction as the antibiotic gene). The constructs were maintained in cells using chloramphenicol.

**Human serum killing assay.** Human serum (10% sera in phosphate-buffered saline [PBS]) was aliquoted into 10-mL tubes, and duplicate samples were tested in each assay. One aliquot (5 mL) was heat treated by incubation at 56°C for 30 min (HTS), while the other aliquot (5 mL) was kept on ice (NS), whereafter 500 μL of appropriate serum was aliquoted into a 24-well plate, labeled, and kept on ice until bacteria were added. One milliliter of bacterial culture at an OD<sub>600</sub> of 0.6 was centrifuged at 13,000 × g for 5 min. The pellet was resuspended in 1 mL PBS and diluted to obtain 1 × 10<sup>6</sup> CFU/50 μL (time zero

[ $T_0$ ] sample) and kept on ice. A 50- $\mu$ L aliquot of the starter culture ( $T_0$ ) was added to the serum and incubated at 37°C for 90 min with shaking (180 rpm). The various dilutions of the starter culture, HTS samples, and NS samples were spread plated on LB agar plates with antibiotics and incubated at 37°C overnight.

**Whole-blood assay.** *K. pneumoniae* B5055 and mutants were grown to mid-log phase. The bacterial cells were pelleted by centrifugation at  $13,000 \times g$  for 5 min. The cells were washed in PBS and diluted to make a final CFU of  $\sim 5 \times 10^7$ /mL. Sterile Vacuette tubes containing lithium heparin (Greiner Bio-One, Frickenhausen, Germany) were used to collect murine or human blood, which was used on the day of collection. To study phagocytosis, 100  $\mu$ L of diluted bacterial culture was added to 300  $\mu$ L of whole heparinized blood, and the mixture was incubated at 37°C for 3 h with rotation. Samples were plated for viable bacterial counts before and after incubation.

**SDS-PAGE and silver stain.** LPS samples were prepared using the proteinase K-hot phenol method described by Marolda et al. (76). Samples were separated with Tricine-SDS-PAGE using 15% polyacrylamide gels, followed by LPS staining and visualization with 0.1% (wt/vol) silver nitrate, as described by Kittelberger and Hilbink (77).

**Method for Western blotting.** The LPS O1 antigen was detected by immunoblotting using the monoclonal antibody I12, as described by Clements et al. (60). Following SDS-PAGE, samples were transferred to nitrocellulose membrane. The primary antibody was used at a dilution of 1:1000. A goat anti-mouse horseradish peroxidase (HRP) conjugate (Bio-Rad) was used as the secondary antibody at a dilution of 1:10,000. Detection was by colorimetric development with TMB (3,3',5,5'-tetramethylbenzidine) membrane peroxidase substrate (Seracare).

**Flow cytometry.** Monoclonal antibodies F1 and I12 (raised against outer membrane proteins [OMPs] of *K. pneumoniae* B5055  $\Delta wza$ ) were used for detection of capsule and LPS by flow cytometry. The bacterial strains were grown overnight in LB broth at 37°C at 180 rpm. One-milliliter aliquots of the overnight culture were centrifuged at  $13,000 \times g$  for 7 min to obtain the cell pellet, which was then washed and resuspended in 1 mL PBS. One hundred-microliter aliquots were centrifuged to pellet the bacteria, followed by removal of the PBS. The pellet was resuspended in (1:50) F1 or (1:250) I12 antibody in 0.2% (wt/vol) bovine serum albumin (BSA) in PBS and incubated at 37°C for 60 min. The samples were centrifuged to remove the supernatant, followed by washing three times with PBS. The pellet was resuspended in 100  $\mu$ L of 1:300 fluorescein isothiocyanate (FITC)-labeled anti-mouse Ig ( $\lambda + K$ ) in 0.2% BSA in PBS or anti-mouse IgG (only for F1 antibodies) in 0.2% BSA in PBS. The samples were incubated at 37°C in the dark for 60 min. The supernatant was removed after centrifugation of the samples, followed by washing three times with PBS. The cells were gently resuspended in 200  $\mu$ L of 4% (vol/vol) formaldehyde and incubated at room temperature for 20 min to kill the bacteria. The sample was centrifuged to remove the formaldehyde supernatant, followed by washing in PBS. The cells were resuspended in 100 to 500  $\mu$ L PBS and analyzed by fluorescence-activated cell sorting (FACS) using FACSort (BD Biosciences, USA) with the appropriate voltage and compensation settings, which were determined by using reference samples (bacteria incubated without primary antibodies).

**Atomic force microscopy.** Strains were maintained on Luria-Bertani (LB) agar at 37°C. LB broth samples inoculated with these cultures were grown for 16 h at 37°C while shaking (180 rpm). Stationary-phase cells were then harvested by centrifugation (10 min at  $3,500 \times g$ ) and washed twice with Milli-Q water ( $18.2 \text{ M}\Omega \text{ cm}^{-1}$ ). The final concentration of bacterial cells in Milli-Q water was approximately  $2 \times 10^8 \text{ CFU mL}^{-1}$ . Cells were adhered to gelatin-coated glass slides to ensure immobilization for AFM measurements. Substrate rigidity is a requirement when measuring cell indentation to ensure that only cell compression contributes to the measurement. The gelatin coating method is described elsewhere (78). Wang et al. (78) found that there is no measurable effect of gelatin deformability on the force profiles of the bacteria. All mechanical measurements were performed within 8 h of removal of the bacteria from growth medium. Bacterium-coated slides were immersed in 10 mM HEPES buffer (pH 7.4) and kept at rest within the calibrated atomic force microscope for at least 40 min before measurements commenced, as described previously (78). AFM measurements were performed using an MFP-3D instrument (Asylum Research, Santa Barbara, CA). Silicon nitride cantilevers were purchased from Bruker (MLCT, Camarillo, CA), with a nominal spring constant of  $0.02 \text{ N m}^{-1}$  and probe radius of 20 nm (according to the manufacturer's specifications). Cantilever spring constants were determined using the thermal tune method (79) included in the MFP-3D software. Calibrated spring constants were within the range of  $0.016$  to  $0.024 \text{ N m}^{-1}$ . All cantilevers used were from the same batch. All tips were cleaned in a BioForce UV/ozone cleaner (BioForce Nanosciences, Inc., Ames, IA) before use. Photodetector sensitivity was measured on a clean silica slide prior to force measurements (80). The slope of the constant compliance region of the force curves obtained was used to convert the deflection,  $d$ , in millivolts to nanometers. The cantilever deflection was then converted into a force,  $F$ , according to Hooke's law,  $F = k \times d$ , where  $k$  is the force constant of the cantilever (81). Cells were imaged in contact mode at a scan rate of 1 Hz at room temperature (typically 20°C). Trace and retrace were monitored to locate the true apex of cells, and force curves were measured at different locations along it. The cell apex was probed during force measurements rather than the cell periphery, which has a high degree of curvature that makes quantification of mechanical properties difficult (82). Imaging was repeated after each collection of force curves to ensure no change in cell morphology had occurred. Force curves were acquired at a loading rate of  $600 \text{ nm s}^{-1}$ . For each cell type, force curves were collected on at least 30 cells from 3 different preparations consisting of at least 7 cells. Eleven force curves were measured along the apex of each cell, and the median curve was selected for analysis and was only included in the analysis if the force curves showed good reproducibility from location to location.

**Bacterial cell indentation and force curve analysis.** As demonstrated previously (36, 83), the force curves that result from the indentation of *K. pneumoniae* cells are comprised of two distinct regions, linear and nonlinear, when working at low electrolyte concentrations. The indentation depth at which the linear portion of the force curve begins provides an estimate of the bacterial capsule thickness, where the contact point (i.e., zero indentation) is defined as the onset of cantilever deflection since long-range noncontact double-layer interactions are negligible in this study. (The electrolyte concentration is 10 mM, which corresponds to a Debye length of ~3 nm.)

## SUPPLEMENTAL MATERIAL

Supplemental material is available online only.

**SUPPLEMENTAL FILE 1**, PDF file, 0.9 MB.

## ACKNOWLEDGMENTS

We acknowledge the generous support of the NHMRC (Program Grant to T.L. and RAS 1092262) and the ARC (DP Grant to N.W. and RAS DP200103110).

We thank Chris Whitfield for very helpful discussions about the models for capsule retention.

## REFERENCES

- Podschun R, Ullmann U. 1998. Klebsiella spp. as nosocomial pathogens: epidemiology, taxonomy, typing methods, and pathogenicity factors. *Clin Microbiol Rev* 11:589–603. <https://doi.org/10.1128/CMR.11.4.589>.
- Ejaz H, Wang N, Wilksch JJ, Page AJ, Cao H, Gujran S, Keane JA, Lithgow T, Ul-Haq I, Dougan G, Strugnell RA, Heinz E. 2017. Phylogenetic analysis of Klebsiella pneumoniae from hospitalized children, Pakistan. *Emerg Infect Dis* 23:1872–1875. <https://doi.org/10.3201/eid2311.170833>.
- Okeke IN, Laxminarayan R, Bhutta ZA, Duse AG, Jenkins P, O'Brien TF, Pablos-Mendez A, Klugman KP. 2005. Antimicrobial resistance in developing countries. Part I. Recent trends and current status. *Lancet Infect Dis* 5:481–493. [https://doi.org/10.1016/S1473-3099\(05\)70189-4](https://doi.org/10.1016/S1473-3099(05)70189-4).
- Yong D, Toleman MA, Giske CG, Cho HS, Sundman K, Lee K, Walsh TR. 2009. Characterization of a new metallo- $\beta$ -lactamase gene, blaNDM-1, and a novel erythromycin esterase gene carried on a unique genetic structure in Klebsiella pneumoniae sequence type 14 from India. *Antimicrob Agents Chemother* 53:5046–5054. <https://doi.org/10.1128/AAC.00774-09>.
- Kumarasamy KK, Toleman MA, Walsh TR, Bagaria J, Butt F, Balakrishnan R, Chaudhary U, Doumith M, Giske CG, Irfan S, Krishnan P, Kumar AV, Maharjan S, Mushtaq S, Noorie T, Paterson DL, Pearson A, Perry C, Pike R, Rao B, Ray U, Sarma JB, Sharma M, Sheridan E, Thirunarayan MA, Turton J, Upadhyay S, Warner M, Welfare W, Livermore DM, Woodford N. 2010. Emergence of a new antibiotic resistance mechanism in India, Pakistan, and the UK: a molecular, biological, and epidemiological study. *Lancet Infect Dis* 10:597–602. [https://doi.org/10.1016/S1473-3099\(10\)70143-2](https://doi.org/10.1016/S1473-3099(10)70143-2).
- Bogdanovich T, Adams-Haduch JM, Tian G-B, Nguyen MH, Kwak EJ, Muto CA, Doi Y. 2011. Colistin-resistant, Klebsiella pneumoniae carbapenemase (KPC)-producing Klebsiella pneumoniae belonging to the international epidemic clone ST258. *Clin Infect Dis* 53:373–376. <https://doi.org/10.1093/cid/cir401>.
- Herridge WP, Shibu P, O'Shea J, Brook TC, Hoyles L. 2020. Bacteriophages of Klebsiella spp., their diversity and potential therapeutic uses. *J Med Microbiol* 69:176–194.
- Motley MP, Diago-Navarro E, Banerjee K, Inzerillo S, Fries BC. 2020. The role of IgG subclass in antibody-mediated protection against carbapenem-resistant Klebsiella pneumoniae. *mBio* 11:e02059-20. <https://doi.org/10.1128/mBio.02059-20>.
- Holt KE, Wertheim H, Zadoks RN, Baker S, Whitehouse CA, Dance D, Jenney A, Connor TR, Hsu LY, Severin J, Brisse S, Cao H, Wilksch J, Gorrie C, Schultz MB, Edwards DJ, Nguyen KV, Nguyen TV, Dao TT, Mensink M, Minh VL, Nhu NT, Schultsz C, Kuntam K, Newton PN, Moore CE, Strugnell RA, Thomson NR. 2015. Genomic analysis of diversity, population structure, virulence, and antimicrobial resistance in Klebsiella pneumoniae, an urgent threat to public health. *Proc Natl Acad Sci U S A* 112:E3574–E3581. <https://doi.org/10.1073/pnas.1501049112>.
- Wyres KL, Lam MMC, Holt KE. 2020. Population genomics of Klebsiella pneumoniae. *Nat Rev Microbiol* 18:344–359. <https://doi.org/10.1038/s41579-019-0315-1>.
- Rocker A, Lacey JA, Belousoff MJ, Wilksch JJ, Strugnell RA, Davies MR, Lithgow T. 2020. Global trends in proteome remodeling of the outer membrane modulate antimicrobial permeability in Klebsiella pneumoniae. *mBio* 11:e00603-20. <https://doi.org/10.1128/mBio.00603-20>.
- Simoons-Smit AM, Verweij-van Vught A, MacLaren DM. 1986. The role of K antigens as virulence factors in Klebsiella. *J Med Microbiol* 21:133–137. <https://doi.org/10.1099/00222615-21-2-133>.
- Orskov F, Orskov I. 1978. Serotyping of Enterobacteriaceae, with special emphasis on K antigen determination, vol 11. Academic Press, Ltd, London, United Kingdom.
- Ørskov I, Fife-Asbury MA. 1977. New Klebsiella capsular antigen, K82, and the deletion of five of those previously assigned. *Int J Syst Bacteriol* 27:386–387. <https://doi.org/10.1099/00207713-27-4-386>.
- Cryz S, Jr, Furer E, Germanier R. 1985. Purification and vaccine potential of Klebsiella capsular polysaccharides. *Infect Immun* 50:225–230. <https://doi.org/10.1128/iai.50.1.225-230.1985>.
- Cryz S, Mortimer P, Cross A, Furer E, Germanier R. 1986. Safety and immunogenicity of a polyvalent Klebsiella capsular polysaccharide vaccine in humans. *Vaccine* 4:15–20. [https://doi.org/10.1016/0264-410x\(86\)90092-7](https://doi.org/10.1016/0264-410x(86)90092-7).
- Cryz SJ, Jr, Mortimer PM, Mansfield V, Germanier R. 1986. Seroepidemiology of Klebsiella bacteremic isolates and implications for vaccine development. *J Clin Microbiol* 23:687–690. <https://doi.org/10.1128/jcm.23.4.687-690.1986>.
- Kiseleva BS, Krasnogolovets VN. 1983. Role of Klebsiella pneumoniae in the etiology of bacterial sepsis. *Zh Mikrobiol Epidemiol Immunobiol* 1983:20–25. (In Russian.)
- Remya P, Shanthi M, Sekar U. 2018. Occurrence and characterization of hyperviscous K1 and K2 serotype in Klebsiella pneumoniae. *J Lab Physicians* 10:283–288. [https://doi.org/10.4103/JLP.JLP\\_48\\_18](https://doi.org/10.4103/JLP.JLP_48_18).
- Jenney AW, Clements A, Farn JL, Wijburg OL, McGlinchey A, Spelman DW, Pitt TL, Kaufmann ME, Liolios L, Moloney MB, Wesselingh SL, Strugnell RA. 2006. Seroepidemiology of Klebsiella pneumoniae in an Australian tertiary hospital and its implications for vaccine development. *J Clin Microbiol* 44:102–107. <https://doi.org/10.1128/JCM.44.1.102-107.2006>.
- Heinz E, Ejaz H, Bartholdson Scott J, Wang N, Gujran S, Pickard D, Wilksch J, Cao H, Haq IU, Dougan G, Strugnell RA. 2019. Resistance mechanisms and population structure of highly drug resistant Klebsiella in Pakistan during the introduction of the carbapenemase NDM-1. *Sci Rep* 9:2392. <https://doi.org/10.1038/s41598-019-38943-7>.
- Laakso DH, Homonylo MK, Wilmot SJ, Whitfield C. 1988. Transfer and expression of the genetic determinants for O and K antigen synthesis in Escherichia coli O9:K(A)30 and Klebsiella sp. O1:K20, in Escherichia coli K12. *Can J Microbiol* 34:987–992. <https://doi.org/10.1139/m88-173>.
- Matsumoto H, Tazaki T. 1971. Genetic mapping of aro, pyl, and pur markers in Klebsiella pneumoniae. *Jpn J Microbiol* 15:11–20. <https://doi.org/10.1111/j.1348-0421.1971.tb00546.x>.
- Arakawa Y, Wacharotayankun R, Nagatsuka T, Ito H, Kato N, Ohta M. 1995. Genomic organization of the Klebsiella pneumoniae cps region responsible for serotype K2 capsular polysaccharide synthesis in the virulent strain Chedid. *J Bacteriol* 177:1788–1796. <https://doi.org/10.1128/jb.177.7.1788-1796.1995>.

25. Chang HY, Lee JH, Deng WL, Fu TF, Peng HL. 1996. Virulence and outer membrane properties of a galU mutant of *Klebsiella pneumoniae* CG43. *Microb Pathog* 20:255–261. <https://doi.org/10.1006/mpat.1996.0024>.
26. Regue M, Hita B, Pique N, Izquierdo L, Merino S, Fresno S, Benedi VJ, Tomas JM. 2004. A gene, *uge*, is essential for *Klebsiella pneumoniae* virulence. *Infect Immun* 72:54–61. <https://doi.org/10.1128/IAI.72.1.54-61.2004>.
27. Fresno S, Jimenez N, Izquierdo L, Merino S, Corsaro MM, De Castro C, Parrilli M, Naldi T, Regue M, Tomas JM. 2006. The ionic interaction of *Klebsiella pneumoniae* K2 capsule and core lipopolysaccharide. *Microbiology (Reading)* 152:1807–1818. <https://doi.org/10.1099/mic.0.28611-0>.
28. Doyle L, Ovchinnikova OG, Myler K, Mallette E, Huang BS, Lowary TL, Kimber MS, Whitfield C. 2019. Biosynthesis of a conserved glycolipid anchor for Gram-negative bacterial capsules. *Nat Chem Biol* 15:632–640. <https://doi.org/10.1038/s41589-019-0276-8>.
29. Fresno S, Jimenez N, Canals R, Merino S, Corsaro MM, Lanzetta R, Parrilli M, Pieretti G, Regue M, Tomas JM. 2007. A second galacturonic acid transferase is required for core lipopolysaccharide biosynthesis and complete capsule association with the cell surface in *Klebsiella pneumoniae*. *J Bacteriol* 189:1128–1137. <https://doi.org/10.1128/JB.01489-06>.
30. Rahn A, Beis K, Naismith JH, Whitfield C. 2003. A novel outer membrane protein, Wzi, is involved in surface assembly of the *Escherichia coli* K30 group 1 capsule. *J Bacteriol* 185:5882–5890. <https://doi.org/10.1128/JB.185.19.5882-5890.2003>.
31. Clements A, Gaboriau F, Duval JF, Farn JL, Jenney AW, Lithgow T, Wijburg OL, Hartland EL, Strugnell RA. 2008. The major surface-associated saccharides of *Klebsiella pneumoniae* contribute to host cell association. *PLoS One* 3:e3817. <https://doi.org/10.1371/journal.pone.0003817>.
32. de Lorenzo V, Herrero M, Jakubzik U, Timmis KN. 1990. Mini-Tn5 transposon derivatives for insertion mutagenesis, promoter probing, and chromosomal insertion of cloned DNA in Gram-negative eubacteria. *J Bacteriol* 172:6568–6572. <https://doi.org/10.1128/jb.172.11.6568-6572.1990>.
33. Geyer H, Schlecht S, Himmelspach K. 1982. Immunochemical properties of oligosaccharide-protein conjugates with *Klebsiella*-K2-specificity. II. Protective capacity of the conjugates and anti-conjugate antibodies against infection with *Klebsiella pneumoniae* O1:K2 in mice. *Med Microbiol Immunol* 171:135–143. <https://doi.org/10.1007/BF02123621>.
34. Sutherland IW. 1972. The exopolysaccharides of *Klebsiella* serotype 2 strains as substrates for phage-induced polysaccharide depolymerases. *J Gen Microbiol* 70:331–338. <https://doi.org/10.1099/00221287-70-2-331>.
35. Regue M, Izquierdo L, Fresno S, Pique N, Corsaro MM, Naldi T, De Castro C, Waidelich D, Merino S, Tomas JM. 2005. A second outer-core region in *Klebsiella pneumoniae* lipopolysaccharide. *J Bacteriol* 187:4198–4206. <https://doi.org/10.1128/JB.187.12.4198-4206.2005>.
36. Mularski A, Wilksch J, Hanssen E, Li J, Tomita T, Pidot SJ, Stinear T, Separovic F, Strugnell D. 2019. A nanomechanical study of the effects of colistin on the *Klebsiella pneumoniae* AJ218 capsule. *Eur Biophys J* 46:351–361. <https://doi.org/10.1007/s00249-016-1178-2>.
37. Bushell SR, Lou H, Wallat GD, Beis K, Whitfield C, Naismith JH. 2010. Crystallization and preliminary diffraction analysis of Wzi, a member of the capsule export and assembly pathway in *Escherichia coli*. *Acta Crystallogr Sect F Struct Biol Cryst Commun* 66:1621–1625. <https://doi.org/10.1107/S1744309110040546>.
38. Yang J, Wilksch JJ, Tan JW, Hocking DM, Webb CT, Lithgow T, Robins-Browne RM, Strugnell RA. 2013. Transcriptional activation of the *mrkA* promoter of the *Klebsiella pneumoniae* type 3 fimbrial operon by the c-di-GMP-dependent MrkH protein. *PLoS One* 8:e79038. <https://doi.org/10.1371/journal.pone.0079038>.
39. Dunstan RA, Bamert RS, Belousoff MJ, Short FL, Barlow CK, Pickard DJ, Wilksch JJ, Schittenhelm RB, Strugnell RA, Dougan G, Lithgow T. 2021. Mechanistic insights into the capsule-targeting depolymerase from a *Klebsiella pneumoniae* bacteriophage. *Microbiol Spectr* 9:e01023-21. <https://doi.org/10.1128/Spectrum.01023-21>.
40. Whitfield C. 2006. Biosynthesis and assembly of capsular polysaccharides in *Escherichia coli*. *Annu Rev Biochem* 75:39–68. <https://doi.org/10.1146/annurev.biochem.75.103004.142545>.
41. Whitfield C, Roberts IS. 1999. Structure, assembly and regulation of expression of capsules in *Escherichia coli*. *Mol Microbiol* 31:1307–1319. <https://doi.org/10.1046/j.1365-2958.1999.01276.x>.
42. Willis LM, Whitfield C. 2013. KpsC and KpsS are retaining 3-deoxy-D-manno-2-ulonic acid (Kdo) transferases involved in synthesis of bacterial capsules. *Proc Natl Acad Sci U S A* 110:20753–20758. <https://doi.org/10.1073/pnas.1312637110>.
43. Mizuta K, Ohta M, Mori M, Hasegawa T, Nakashima I, Kato N. 1983. Virulence for mice of *Klebsiella* strains belonging to the O1 group: relationship to their capsular (K) types. *Infect Immun* 40:56–61. <https://doi.org/10.1128/iai.40.1.56-61.1983>.
44. Goslings WRO, Snijders EP. 1936. Zentralbl. Bakteriol. Parasitenkd. Infektionskr. Hyg. Abt I Orig 136:1–24.
45. Whitfield C, Trent MS. 2014. Biosynthesis and export of bacterial lipopolysaccharides. *Annu Rev Biochem* 83:99–128. <https://doi.org/10.1146/annurev-biochem-060713-035600>.
46. Somerville JE, Cassiano L, Bainbridge B, Cunningham MD, Darveau RP. 1996. A novel *Escherichia coli* lipid A mutant that produces an antiinflammatory lipopolysaccharide. *J Clin Invest* 97:359–365. <https://doi.org/10.1172/JCI118423>.
47. Karow M, Georgopoulos C. 1992. Isolation and characterization of the *Escherichia coli* *msbB* gene, a multicopy suppressor of null mutations in the high-temperature requirement gene *htrB*. *J Bacteriol* 174:702–710. <https://doi.org/10.1128/jb.174.3.702-710.1992>.
48. Somerville JE, Cassiano L, Darveau RP. 1999. *Escherichia coli* *msbB* gene as a virulence factor and a therapeutic target. *Infect Immun* 67:6583–6590. <https://doi.org/10.1128/IAI.67.12.6583-6590.1999>.
49. Khan SA, Everest P, Servos S, Foxwell N, Zahringer U, Brade H, Rietschel ET, Dougan G, Charles IG, Maskell DJ. 1998. A lethal role for lipid A in *Salmonella* infections. *Mol Microbiol* 29:571–579. <https://doi.org/10.1046/j.1365-2958.1998.00952.x>.
50. Low KB, Ittensohn M, Le T, Platt J, Sodi S, Amoss M, Ash O, Carmichael E, Chakraborty A, Fischer J, Lin SL, Luo X, Miller SI, Zheng L, King I, Pawelek JM, Bermudes D. 1999. Lipid A mutant *Salmonella* with suppressed virulence and TNF $\alpha$  induction retain tumor-targeting in vivo. *Nat Biotechnol* 17:37–41. <https://doi.org/10.1038/5205>.
51. Clements A, Tull D, Jenney AW, Farn JL, Kim S-H, Bishop RE, McPhee JB, Hancock REW, Hartland EL, Pearse MJ, Wijburg OLC, Jackson DC, McConville MJ, Strugnell RA. 2007. Secondary acylation of *Klebsiella pneumoniae* lipopolysaccharide contributes to sensitivity to antibacterial peptides. *J Biol Chem* 282:15569–15577. <https://doi.org/10.1074/jbc.M701454200>.
52. Strauch KL, Johnson K, Beckwith J. 1989. Characterization of *degP*, a gene required for proteolysis in the cell envelope and essential for growth of *Escherichia coli* at high temperature. *J Bacteriol* 171:2689–2696. <https://doi.org/10.1128/jb.171.5.2689-2696.1989>.
53. Reddy VS, Shlykov MA, Castillo R, Sun EI, Saier MH, Jr. 2012. The major facilitator superfamily (MFS) revisited. *FEBS J* 279:2022–2035. <https://doi.org/10.1111/j.1742-4658.2012.08588.x>.
54. Li W, Wen L, Li C, Chen R, Ye Z, Zhao J, Pan J. 2016. Contribution of the outer membrane protein *OmpW* in *Escherichia coli* to complement resistance from binding to factor H. *Microb Pathog* 98:57–62. <https://doi.org/10.1016/j.micpath.2016.06.024>.
55. Heinrichs DE, Monteiro MA, Perry MB, Whitfield C. 1998. The assembly system for the lipopolysaccharide R2 core-type of *Escherichia coli* is a hybrid of those found in *Escherichia coli* K-12 and *Salmonella enterica*. Structure and function of the R2 WaaK and WaaL homologs. *J Biol Chem* 273:8849–8859. <https://doi.org/10.1074/jbc.273.15.8849>.
56. Tomas A, Lery L, Regueiro V, Perez-Gutierrez C, Martinez V, Moranta D, Llobet E, Gonzalez-Nicolau M, Insua JL, Tomas JM, Sansonetti PJ, Tournebise R, Bengoechea JA. 2015. Functional genomic screen identifies *Klebsiella pneumoniae* factors implicated in blocking nuclear factor kappaB (NF- $\kappa$ B) signaling. *J Biol Chem* 290:16678–16697. <https://doi.org/10.1074/jbc.M114.621292>.
57. Bushell SR, Mainprize IL, Wear MA, Lou H, Whitfield C, Naismith JH. 2013. Wzi is an outer membrane lectin that underpins group 1 capsule assembly in *Escherichia coli*. *Structure* 21:844–853. <https://doi.org/10.1016/j.str.2013.03.010>.
58. Simon R, Priefer U, Pühler A. 1983. A broad host range mobilization system for *in vivo* genetic engineering: transposon mutagenesis in Gram negative bacteria. *Nat Biotechnol* 1:784–791. <https://doi.org/10.1038/nbt1183-784>.
59. Wilksch JJ, Yang J, Clements A, Gabbe JL, Short KR, Cao H, Cavaliere R, James CE, Whitchurch CB, Schembri MA, Chuah ML, Liang ZX, Wijburg OL, Jenney AW, Lithgow T, Strugnell RA. 2011. MrkH, a novel c-di-GMP-dependent transcriptional activator, controls *Klebsiella pneumoniae* biofilm formation by regulating type 3 fimbriae expression. *PLoS Pathog* 7:e1002204. <https://doi.org/10.1371/journal.ppat.1002204>.
60. Clements A, Jenney AW, Farn JL, Brown LE, Deliyannis G, Hartland EL, Pearse MJ, Maloney MB, Wesselingh SL, Wijburg OL, Strugnell RA. 2008. Targeting subcapsular antigens for prevention of *Klebsiella pneumoniae* infections. *Vaccine* 26:5649–5653. <https://doi.org/10.1016/j.vaccine.2008.07.100>.

61. Wang H, Wilksch JJ, Chen L, Tan JW, Strugnell RA, Gee ML. 2017. Influence of fimbriae on bacterial adhesion and viscoelasticity and correlations of the two properties with biofilm formation. *Langmuir* 33:100–106. <https://doi.org/10.1021/acs.langmuir.6b03764>.
62. Wang H, Wilksch JJ, Strugnell RA, Gee ML. 2015. Role of capsular polysaccharides in biofilm formation: an AFM nanomechanics study. *ACS Appl Mater Interfaces* 7:13007–13013. <https://doi.org/10.1021/acsami.5b03041>.
63. Williams DM, Ovchinnikova OG, Koizumi A, Mainprize IL, Kimber MS, Lowary TL, Whitfield C. 2017. Single polysaccharide assembly protein that integrates polymerization, termination, and chain-length quality control. *Proc Natl Acad Sci U S A* 114:E1215–E1223. <https://doi.org/10.1073/pnas.1613609114>.
64. Rahman MM, Gu XX, Tsai CM, Kolli VS, Carlson RW. 1999. The structural heterogeneity of the lipooligosaccharide (LOS) expressed by pathogenic non-typeable *Haemophilus influenzae* strain NTHi 9274. *Glycobiology* 9:1371–1380. <https://doi.org/10.1093/glycob/9.12.1371>.
65. Mandrell RE, Apicella MA. 1993. Lipo-oligosaccharides (LOS) of mucosal pathogens: molecular mimicry and host-modification of LOS. *Immunobiology* 187:382–402. [https://doi.org/10.1016/S0171-2985\(11\)80352-9](https://doi.org/10.1016/S0171-2985(11)80352-9).
66. Clements A. 2007. Investigation of virulence determinants of *Klebsiella pneumoniae*. PhD. University of Melbourne, Melbourne, Australia.
67. Maneval WE. 1941. Staining bacteria and yeasts with acid dyes. *Stain Technol* 16:13–19. <https://doi.org/10.3109/10520294109106189>.
68. Campos MA, Vargas MA, Regueiro V, Llompart CM, Albertí S, Bengoechea JA. 2004. Capsule polysaccharide mediates bacterial resistance to antimicrobial peptides. *Infect Immun* 72:7107–7114. <https://doi.org/10.1128/IAI.72.12.7107-7114.2004>.
69. Bitter T, Muir HM. 1962. A modified uronic acid carbazole reaction. *Anal Biochem* 4:330–334. [https://doi.org/10.1016/0003-2697\(62\)90095-7](https://doi.org/10.1016/0003-2697(62)90095-7).
70. Westphal O, Jann K. 1963. Bacterial lipopolysaccharides extraction with phenol-water and further applications of the procedure. *Methods Carbohydr Chem* 5:83–91.
71. van den Hoogen BM, van Weeren PR, Lopes-Cardozo M, van Golde LMG, Barneveld A, van de Lest CHA. 1998. A microtiter plate assay for the determination of uronic acids. *Anal Biochem* 257:107–111. <https://doi.org/10.1006/abio.1997.2538>.
72. Kwon YM, Ricke SC. 2000. Efficient amplification of multiple transposon-flanking sequences. *J Microbiol Methods* 41:195–199. [https://doi.org/10.1016/S0167-7012\(00\)00159-7](https://doi.org/10.1016/S0167-7012(00)00159-7).
73. Herring CD, Glasner JD, Blattner FR. 2003. Gene replacement without selection: regulated suppression of amber mutations in *Escherichia coli*. *Gene* 311:153–163. [https://doi.org/10.1016/S0378-1119\(03\)00585-7](https://doi.org/10.1016/S0378-1119(03)00585-7).
74. Datsenko KA, Wanner BL. 2000. One-step inactivation of chromosomal genes in *Escherichia coli* K-12 using PCR products. *Proc Natl Acad Sci U S A* 97:6640–6645. <https://doi.org/10.1073/pnas.120163297>.
75. Chang AC, Cohen SN. 1978. Construction and characterization of amplifiable multicopy DNA cloning vehicles derived from the P15A cryptic miniplasmid. *J Bacteriol* 134:1141–1156. <https://doi.org/10.1128/jb.134.3.1141-1156.1978>.
76. Marolda CL, Lahiry P, Vinés E, Saldías S, Valvano MA. 2006. Micromethods for the characterisation of lipid A-core and O-antigen lipopolysaccharide. *Methods Mol Biol* 347:237–252. <https://doi.org/10.1385/1-59745-167-3:237>.
77. Kittelberger R, Hilbink F. 1993. Sensitive silver-staining detection of bacterial lipopolysaccharides in polyacrylamide gels. *J Biochem Biophys Methods* 26:81–86. [https://doi.org/10.1016/0165-022x\(93\)90024-i](https://doi.org/10.1016/0165-022x(93)90024-i).
78. Wang H, Wilksch JJ, Lithgow T, Strugnell RA, Gee ML. 2013. Nanomechanics measurements of live bacteria reveal a mechanism for bacterial cell protection: the polysaccharide capsule in *Klebsiella* is a responsive polymer hydrogel that adapts to osmotic stress. *Soft Matter* 9:7560–7567. <https://doi.org/10.1039/c3sm51325d>.
79. Hutter JL, Bechhoefer J. 1993. Calibration of atomic-force microscope tips. *Rev Sci Instrum* 64:1868–1873. <https://doi.org/10.1063/1.1143970>.
80. Velegol SB, Logan BE. 2002. Contributions of bacterial surface polymers, electrostatics, and cell elasticity to the shape of AFM force curves. *Langmuir* 18:5256–5262. <https://doi.org/10.1021/la011818g>.
81. Radmacher M, Fritz M, Hansma PK. 1995. Imaging soft samples with the atomic force microscope: gelatin in water and propanol. *Biophysical J* 69:264–270. [https://doi.org/10.1016/S0006-3495\(95\)79897-6](https://doi.org/10.1016/S0006-3495(95)79897-6).
82. Gaboriaud F, Parcha BS, Gee ML, Holden JA, Strugnell RA. 2008. Spatially resolved force spectroscopy of bacterial surfaces using force-volume imaging. *Colloids Surf B Biointerfaces* 62:206–213. <https://doi.org/10.1016/j.colsurfb.2007.10.004>.
83. Mularski A, Wilksch JJ, Hanssen E, Strugnell RA, Separovic F. 2016. Atomic force microscopy of bacteria reveals the mechanobiology of pore forming peptide action. *Biochim Biophys Acta* 1858:1091–1098. <https://doi.org/10.1016/j.bbamem.2016.03.002>.
84. Raetz CR, Whitfield C. 2002. Lipopolysaccharide endotoxins. *Annu Rev Biochem* 71:635–700. <https://doi.org/10.1146/annurev.biochem.71.110601.135414>.
85. Dong C, Beis K, Nesper J, Brunkan-Lamontagne AL, Clarke BR, Whitfield C, Naismith JH. 2006. Wza the translocon for *E. coli* capsular polysaccharides defines a new class of membrane protein. *Nature* 444:226–229. <https://doi.org/10.1038/nature05267>.